



PB 24 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 27 February 2024

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 March 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 2) 2024*.
- (2) This instrument may also be cited as PB 24 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 March 2024.	1 March 2024
2. Schedule 1	1 March 2024.	1 March 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 March 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

After:

Amitriptyline	Tablet containing amitriptyline hydrochloride 50 mg	Oral	ENTRIP	(a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand
---------------	---	------	--------	--

insert:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Norvapine	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand

2 Schedule 1

Omit:

Atorvastatin	Tablet 20 mg (as calcium)	Oral	Atorvastatin GH	Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand
--------------	---------------------------	------	-----------------	---

3 Schedule 1

Omit:

Bisoprolol	Tablet containing bisoprolol fumarate 10 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

4 Schedule 1

Omit:

Clopidogrel	Tablet 75 mg (as besilate)	Oral	Clopidogrel GH	Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand
-------------	----------------------------	------	----------------	---

5 Schedule 1

After:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	Diclofenac Sandoz	between 1 November 2023 and 30 April 2024—4 months stock by reference to usual demand
------------	--	------	-------------------	---

insert:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 25 mg	Oral	Fenac 25	between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand
------------	--	------	----------	--

6 Schedule 1

Omit:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	Fenac	(a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand
------------	--	------	-------	---

substitute:

Diclofenac	Tablet (enteric coated) containing diclofenac sodium 50 mg	Oral	Fenac	between 1 March 2024 and 31 March 2024—0 months stock by reference to usual demand
------------	--	------	-------	--

7 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-10 mg	Oral	EZESIM 10/10	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
----------------------------	--------------------	------	--------------	---

8 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-20 mg	Oral	EZESIM 10/20	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
----------------------------	--------------------	------	--------------	---

9 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	EZESIM 10/40	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
----------------------------	--------------------	------	--------------	---

10 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	EZESIM 10/80	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
----------------------------	--------------------	------	--------------	---

11 Schedule 1

Omit:

Filgrastim	Injection 300 micrograms in 1 mL	Injection	Neupogen	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
Filgrastim	Injection 480 micrograms in 1.6 mL	Injection	Neupogen	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

12 Schedule 1

After:

Folic acid	Tablet 500 micrograms	Oral	Megafol 0.5	4 months stock by reference to usual PBS demand
------------	-----------------------	------	-------------	---

insert:

Folinic acid	Injection containing calcium folinate equivalent to 100 mg folinic acid in 10 mL	Injection	Leucovorin Calcium (Pfizer Australia Pty Ltd)	between 1 March 2024 and 31 July 2024— 0 months stock by reference to usual demand
--------------	--	-----------	---	---

13 Schedule 1

Omit:

Glucose indicator-urine	Test strips, 50 (Diastix)	For External Use	Diastix	between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand
-------------------------	---------------------------	------------------	---------	--

14 Schedule 1

Omit:

Levetiracetam	Tablet 1 g	Oral	Levecetam 1000	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 250 mg	Oral	Levecetam 250	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 500 mg	Oral	Levecetam 500	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

15 Schedule 1

Omit:

Mitozantrone	Injection 20 mg (as hydrochloride) in 10 mL	Injection	Onkotrone	between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand
--------------	---	-----------	-----------	--

16 Schedule 1

Omit:

Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
-------------------	---	------	----------	---

substitute:

Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	CellCept	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
-------------------	---	------	----------	--

17 Schedule 1

Omit:

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
-------------------	--	------	----------	---

substitute:

Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand
-------------------	--	------	----------	--

18 Schedule 1

Omit:

Telmisartan	Tablet 40 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
-------------	--------------	------	------------------	---

Telmisartan	Tablet 80 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
-------------	--------------	------	------------------	---

19 Schedule 1

After:

Topiramate	Tablet 100 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
------------	---------------	------	----------------	---

insert:

Topiramate	Tablet 100 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	---------------	------	---------	--

20 Schedule 1

After:

Topiramate	Tablet 200 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
------------	---------------	------	----------------	---

insert:

Topiramate	Tablet 200 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024—0 months stock by reference to usual demand
------------	---------------	------	---------	--

21 Schedule 1

	After:				
Topiramate	Tablet 25 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand	
	insert:				
Topiramate	Tablet 25 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024— 0 months stock by reference to usual demand	

22 Schedule 1

	After:			
Topiramate	Tablet 50 mg	Oral	APO-Topiramate	3 months stock by reference to usual demand
	insert:			
Topiramate	Tablet 50 mg	Oral	Topamax	between 1 March 2024 and 30 April 2024— 0 months stock by reference to usual demand